Member Info for EmeraldCarrots

Here's a breakdown by region:

Dublin (Greater Dublin Area):

The Coombe Women & Infants University Hospital: A major public maternity hospital.

National Maternity Hospital (Holles Street): Another key public hospital.

***Rotunda Hospital: Ireland's oldest continuously operating maternity hospital*** - See RNS is using NOW.

Mater Private Hospital (Dublin): A private option.

Cork & Munster:

Cork University Maternity Hospital (CUMH): Major public facility.

Bon Secours Hospital (Cork): Well-known private maternity.

Mercy University Hospital (Cork): Has maternity services.

University Maternity Hospital Limerick (UMHL): Public hospital for the Mid-West.

Waterford University Hospital: Offers maternity services.

Connacht & West:

Galway University Hospitals (University Hospital Galway): Major hub for the West.

Mayo University Hospital (Castlebar): Offers maternity.

Sligo University Hospital: Provides maternity services.

Ulster & North:

Letterkenny University Hospital: Key maternity for Donegal.

Our Lady of Lourdes Hospital (Drogheda): Serves Louth/Meath.

Midlands & East:

Midland Regional Hospital, Tullamore & Portlaoise: Provide maternity.

Our Lady of Lourdes Hospital (Drogheda): Serves the border.

=============================

A load more potential here. With the Rotunda Hospital already using the MT-RNR1, how many more will?????

The sp could explode North....................

If a bid turns up over the next few months he will more than double his investment I think. Of course Genedrive need another sales boost from somewhere. Lots of irons in the fire. They should be able to build on the excellent country wide NHS Scotland rollout and get other countries on board.

On possible funding issues in 3 or 4 months as there are multiple chances of very positive news during that time. All sorts could happen including Saudi Arabia adopting for all their hospitals, other Contries the same and indeed the possiblility of a bid. Maybe far more English NHS hospitals will get on board too.

All IMHO.

Mraveragetrader.

"Is the SP going to up or down on this news...?"

======================

Well, without it we were up the creek without a paddle, and some holders would have sold in case of administration. So it is very good news. The sp should go what.......... 1.4p ish at least IMHO.

Mr Nugent! The other Directors need to step up too.

Https://www.lse.co.uk/rns/GDR/agreement-of-shareholder-loan-2vy92vbptu0pzoz.html

Up 25%.

Up 25%.

Https://www.bbc.co.uk/news/articles/cj38ymeyg4mo

Use Parsortix to catch the circulating tumor cells to see how the cancer reacts to the treatment...............

Will return to the sp. Loan RNS expected any time now. Mr Gilham could help by buyng a more substancial amount IMHO.

Https://www.bbc.co.uk/news/articles/cj38ymeyg4mo

Are they a bit thick? You would have thought they would be highly intelligent. Although a lot of people that can read and remember data in books to get their qualifications have no common sense at all, as we know. Cellbxhealth have the Parsortix machine that can catch live, intact, uncontaminated circulating tumor cells from a standard blood sample. Yet Immatics seem to be almost the only Company who has even realised what data analysing CTC's can give you.

It's a mad World.

Mad.

Parsortix is involved with gene editing as an upstream technology for isolating rare live cancer cells, such as circulating tumor cells (CTCs), from blood samples, which can then be subjected to various advanced molecular analyses, including those that use or involve gene editing techniques like CRISPR. The Parsortix system itself does not perform gene editing, but enables the necessary sample preparation.

The Role of Parsortix

Cell Isolation: The Parsortix system, developed by ANGLE plc, is a microfluidic device that enriches and harvests intact CTCs from whole blood based on their physical characteristics (size and deformability), not specific surface markers. This label-free method is crucial as it captures a wider range of cancer cell types, including those that have undergone epithelial-to-mesenchymal transition (EMT) and might be missed by antibody-based systems.

Harvesting Live Cells: The system's key advantage is its ability to harvest viable cells, preserving their genetic material (DNA, RNA) and proteins.

Downstream Analysis: These isolated, viable cells can then be used for a wide range of downstream analyses and research, including:

Genetic Profiling: Studying gene expression, identifying mutations, and performing RNA sequencing.

Studying Metastasis: Research using Parsortix has identified genes involved in cancer spread and highlighted the importance of genetic diversity in CTC clusters.

Enabling Gene Editing Research: The ability to isolate live, intact CTCs facilitates research into new therapeutic targets. Studies have used models in combination with a CRISPR-based approach to identify targetable players in cancer metastasis. This means researchers can use the cells isolated by the Parsortix system in experiments that involve gene editing to better understand cancer biology and potentially develop new treatments.

In essence, Parsortix is a critical enabler for sophisticated molecular research, providing high-purity, viable cell samples that can be interrogated using cutting-edge techniques like gene editing.

================================

But no one thinks is is worth a penny. LOL! HA HA HA!!!

GloriaMarket.

"Perhaps the other shareholder they are speaking to is Dr Ian Gilham.."

==================================

Well Gloria, Mr Gilham is definately NOT a major share holder at the moment as we all know. He seems happy for other people to buy shares in GDR when he only has a very modest amount himself, considering how well off he is rumoured to be. Maybe the rumour is untrue and he just can't afford to buy more?

Https://www.bbc.co.uk/news/articles/cj38ymeyg4mo

Nugent news hoped for!

But I wonder what else he has negotiated? Getting the overheads down further maybe?

Researcher1

"Anyone heard whether Alvar are holding their short ? One would imagine they'll cash in profit on or around the 18th...."

https://www.shorttracker.co.uk/company/GB0034330679/

==================================

Looks like it. Seesms risky now Cellbxhealth have both the Qiagen and Myriad Genetics collaborations. One deal and the sp could easily triple or more IMHO.

And there is more!

Immatics Inc. uses the Parsortix system in its IMA203 cancer drug trials because the therapy specifically targets the PRAME protein, and Parsortix is a non-invasive liquid biopsy technology used to analyze circulating tumor cells (CTCs) for the presence of this specific protein target (PRAME) to screen and monitor patients. This approach is crucial for identifying which patients are most likely to respond to the treatment.

Rationale for Using Parsortix in IMA203 Trials

The key reasons for using the Parsortix system in the IMA203 trials are rooted in the drug's mechanism and the unique capabilities of the Parsortix platform:

Targeted Therapy Requirement: IMA203 is an adoptive T cell therapy that targets an HLA-A02-presented peptide derived from the PRAME protein. The drug is effective only in patients whose cancer cells express this specific target and who also have the matching HLA-A02:01 status. Therefore, accurate screening for PRAME expression is essential for patient selection.

Liquid Biopsy for Patient Selection: The Parsortix system is used to capture intact, live CTCs from a simple blood sample (a "liquid biopsy"). This non-invasive method allows for the analysis of the PRAME protein expression on these cells, either as an alternative or a supplement to a potentially complex and invasive solid tumor biopsy.

Monitoring Treatment Effectiveness: By repeatedly analyzing CTCs via liquid biopsy throughout the trial, researchers can monitor the expression levels of PRAME and assess the pharmacodynamic effects of the drug, helping to determine the treatment's effectiveness over time.

Epitope-Independent Capture: The Parsortix system captures cells based on their size and deformability, rather than using cell surface markers (epitope-independent). This is advantageous because cancer cells can change their characteristics (e.g., during epithelial-to-mesenchymal transition, EMT), which might cause them to be missed by antibody-based capture systems. This ensures a more comprehensive capture of the entire CTC population for analysis.

Why Not in Other Trials?

The use of Parsortix is tailored to the specific diagnostic and monitoring needs of a given trial:

Different Mechanisms of Action: Immatics' other cancer drug trials likely involve different targets or therapeutic mechanisms that may not require the specific CTC analysis capabilities provided by Parsortix. Other trials might rely on different biomarkers (e.g., ctDNA, general protein analysis) or established diagnostic methods that do not necessitate the capture of intact CTCs.

Trial Phase and Design: The specific phase (e.g., Phase 1 vs. Phase 3) and design of a clinical trial dictate the type of data needed. Early-stage trials may have different biomarker screening requirements than later-stage, registration-enabling trials like the SUPRAME Phase 3 study.

Drug trials. Digging deeper here. Parsortix might be crucial for this potential cancer drug treatment.

======================

A.I.

Why do Immatics Inc. use Parsortix in their IMA(203) cancer drug trials but not in other cancer drug trials?

Immatics Inc. uses the Parsortix system for its IMA203 (anzu-cel) cancer drug trials and at least two other trials as a core component of its "liquid biopsy" approach to identify and monitor the specific PRAME target protein expression on circulating tumor cells (CTCs).

Why Parsortix is Used in IMA203 Trials

The specific use of the Parsortix system relates directly to the mechanism of action of IMA203 and the unique requirements for patient screening and monitoring in T-cell receptor (TCR) therapies.

PRAME Target Identification: The IMA203 therapy is an engineered T-cell therapy that targets a specific peptide derived from the PRAME protein, which is expressed inside cancer cells. For the drug to be effective, the patient's cancer cells must display this particular PRAME target on their surface, and they must be HLA-A*02 positive.

Non-Invasive Patient Stratification: The Parsortix system allows Immatics to capture intact, viable CTCs from a simple blood draw (a "liquid biopsy"), which is much less invasive than a traditional solid tissue biopsy. This enables them to screen a broad range of cancer patients efficiently to determine if they are suitable candidates for the trial, i.e., if their tumors are PRAME-positive.

Monitoring and Analysis: The captured CTCs can be analyzed for DNA, RNA, and protein biomarkers, including the PRAME protein expression status, allowing researchers to monitor the drug's effectiveness over time and track how the tumor changes or develops resistance.

Harvesting Viable Cells: A key advantage of the Parsortix system is its ability to harvest live, intact, and uncontaminated CTCs based on their size and deformability, rather than using a general antibody-based capture method. This is crucial for the detailed, multi-platform molecular analysis required for developing precision cancer therapies.

Use in Other Trials

Contrary to the premise that it's only used for IMA203, reports indicate Immatics uses the Parsortix system in at least three of their cancer drug trials, including the Phase 3 SUPRAME trial for IMA203 (anzu-cel). The specific details for other trials (IMA201, IMA202, IMA204) are less publicized, but the rationale for using Parsortix likely applies to any of their therapies that require the identification and monitoring of specific intracellular protein targets (like PRAME) via CTC analysis.

https://immatics.com/our-pipeline/

QIAGEN has master collaboration agreements with more than 30 pharmaceutical and biotech companies to develop and commercialize companion diagnostics. These partnerships aim to advance precision medicine by creating diagnostic tests that help tailor patient treatment to specific genetic profiles. Key partners mentioned in various company communications include:

Amgen

AstraZeneca

Boehringer-Ingelheim

Lilly

Merck

Myriad Genetics

Neuron23

Pfizer

Servier

============================

From the RNS:-

"The agreement enables QIAGEN to offer the Parsortix platform to its pharmaceutical partners as part of collaborative projects combining CTC enrichment and analysis with QIAGEN's PCR, digital PCR, and NGS workflows. These projects are expected to support drug development programmes, biomarker discovery, and early-stage companion diagnostic feasibility studies. Under the agreement, QIAGEN may contract directly with pharmaceutical partners, outsourcing exploratory CTC projects to CellBxHealth. The projects will integrate the Parsortix platform with QIAGEN's molecular analysis tools to provide deeper insights into tumour biology and therapeutic response.".

So the Qiagen collaboration means any of these Companies can outsource exploratory CTC projects to CellBxHealth via Qiagen. Immatics have clealy found the live, intact, uncontaminated CTC's are very useful in 3 of their cancer drug trials, one of which is in phase 3 and another in phase 2. I can't see any way on Earth one or more of these Companies won't find Parsortix extremely useful, if not critical in future cancer driug trials.

All IMHO.